Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Pharma in the UK
In 2021, the UK was named the sixth biggest pharmaceutical market, but it’s facing challenges to further growth. Read to find out more.
Access to oncology treatments, diversity and lessons in leadership
The GOLD team are joined by Dr Zsuzsanna Devecseri, Vice President and Head of Global Oncology Medical, Sanofi Genzyme, to discuss her career journey and varied experience within the pharmaceutical industry.
3
Mins
4 Apr 2023
Widal Positivity: Tuberculosis Diagnosis and Fluoroquinolone Resistance
Drug resistance among patients with tuberculosis (TB) is an emergent topic that requires intervention. According to a survey of TB drug resistance in India, resistance to any fluoroquinolones (FQ) reported in cases of multidrug resistance (MDR) to TB was 21.82%.
Advancing diversity in clinical trials
This infographic explores the diversity of patient populations in US clinical trials and the pharmaceutical industry’s efforts to address this and improve outcomes.
6
Mins
31 Mar 2023
Interview: Hannah Gower
Hannah Gower | Cardiology and Internal Medicine Speciality Registrar, Royal Cornwall Hospitals NHS Trust, UK
31 Mar 2023
Rheumatology Through Time
Adam Brown joins Jonathan to discuss teaching in rheumatology and the history of rheumatological conditions. Listen now!
5
Mins
31 Mar 2023
Imaging After Histotripsy: A Non-invasive, Non-thermal Therapy for Cancer
Histotripsy is a non-invasive, non-thermal, and non-ionising focused ultrasound (US) treatment method that destroys tissue through mechanical disruption caused by cavitation. Short-duration (<20 μs) high-pressure US pulses cause the rapid expansion and collapse of endogenous gas bubbles in targeted tissue.
2
Mins
30 Mar 2023
Interview: Juan Gómez Rivas
Juan Gómez Rivas | Urology Consultant, Hospital Clinico San Carlos, Madrid, Spain; Assistant Professor, Universidad Complutense de Madrid, Spain
March 2023
EMJ Hepatology 11 [Supplement 1] 2023
Cholestatic liver diseases include primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and progressive familial intrahepatic cholestasis (PFIC). In all of these conditions, cholestatic itch is a major symptom that can severely and chronically impact a person’s quality of life (QoL).
29 Mar 2023
The New International Wound Infection Institute’s (IWII) Consensus Document: Implementation into Clinical Practice
This webinar discusses the new International Wound Infection Institute’s Consensus Document, which details up-to-date best practice guidelines for wound infection management.
←
1
2
3
…
420
421
422
423
424
425
426
…
1,123
1,124
1,125
→
We’ve noticed you’re accessing
from
North/South America.
View
View